vs
IOVANCE BIOTHERAPEUTICS, INC.（IOVA）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC BANCORP INC的季度营收约是IOVANCE BIOTHERAPEUTICS, INC.的1.1倍（$94.3M vs $86.8M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $-61.9M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs -11.5%）
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
IOVA vs RBCAA — 直观对比
营收规模更大
RBCAA
是对方的1.1倍
$86.8M
营收增速更快
IOVA
高出12.4%
5.3%
自由现金流更多
RBCAA
多$223.0M
$-61.9M
两年增速更快
IOVA
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.8M | $94.3M |
| 净利润 | — | $22.8M |
| 毛利率 | 67.4% | — |
| 营业利润率 | -84.7% | 29.3% |
| 净利率 | — | 24.2% |
| 营收同比 | 17.7% | 5.3% |
| 净利润同比 | — | 20.0% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IOVARBCAA
| Q4 25 | $86.8M | $94.3M | ||
| Q3 25 | $67.5M | $93.5M | ||
| Q2 25 | $60.0M | $93.8M | ||
| Q1 25 | $49.3M | $135.8M | ||
| Q4 24 | $73.7M | $89.5M | ||
| Q3 24 | $58.6M | $88.1M | ||
| Q2 24 | $31.1M | $86.9M | ||
| Q1 24 | $715.0K | $120.3M |
净利润IOVARBCAA
| Q4 25 | — | $22.8M | ||
| Q3 25 | $-91.3M | $29.7M | ||
| Q2 25 | $-111.7M | $31.5M | ||
| Q1 25 | $-116.2M | $47.3M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $-83.5M | $26.5M | ||
| Q2 24 | $-97.1M | $25.2M | ||
| Q1 24 | $-113.0M | $30.6M |
毛利率IOVARBCAA
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
营业利润率IOVARBCAA
| Q4 25 | -84.7% | 29.3% | ||
| Q3 25 | -140.7% | 40.4% | ||
| Q2 25 | -189.8% | 43.0% | ||
| Q1 25 | -245.8% | 44.1% | ||
| Q4 24 | -117.5% | 25.8% | ||
| Q3 24 | -152.1% | 38.4% | ||
| Q2 24 | -327.6% | 37.0% | ||
| Q1 24 | -16464.6% | 32.2% |
净利率IOVARBCAA
| Q4 25 | — | 24.2% | ||
| Q3 25 | -135.3% | 31.8% | ||
| Q2 25 | -186.2% | 33.5% | ||
| Q1 25 | -235.5% | 34.8% | ||
| Q4 24 | — | 21.2% | ||
| Q3 24 | -142.7% | 30.1% | ||
| Q2 24 | -312.2% | 29.0% | ||
| Q1 24 | -15800.8% | 25.4% |
每股收益（稀释后）IOVARBCAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | — | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $297.0M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $698.6M | $1.1B |
| 总资产 | $913.2M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IOVARBCAA
| Q4 25 | $297.0M | $220.0M | ||
| Q3 25 | $300.8M | $484.2M | ||
| Q2 25 | $301.2M | $484.8M | ||
| Q1 25 | $359.7M | $793.0M | ||
| Q4 24 | $323.8M | $432.2M | ||
| Q3 24 | $397.5M | $530.9M | ||
| Q2 24 | $412.5M | $400.1M | ||
| Q1 24 | $356.2M | $546.4M |
股东权益IOVARBCAA
| Q4 25 | $698.6M | $1.1B | ||
| Q3 25 | $702.3M | $1.1B | ||
| Q2 25 | $698.5M | $1.1B | ||
| Q1 25 | $767.9M | $1.0B | ||
| Q4 24 | $710.4M | $992.0M | ||
| Q3 24 | $773.5M | $979.7M | ||
| Q2 24 | $768.5M | $955.4M | ||
| Q1 24 | $680.0M | $935.6M |
总资产IOVARBCAA
| Q4 25 | $913.2M | $7.0B | ||
| Q3 25 | $904.9M | $7.0B | ||
| Q2 25 | $907.4M | $7.0B | ||
| Q1 25 | $966.7M | $7.1B | ||
| Q4 24 | $910.4M | $6.8B | ||
| Q3 24 | $991.1M | $6.7B | ||
| Q2 24 | $964.3M | $6.6B | ||
| Q1 24 | $869.8M | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.6M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $-61.9M | $161.1M |
| 自由现金流率自由现金流/营收 | -71.3% | 170.9% |
| 资本支出强度资本支出/营收 | 10.7% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | $-336.2M | $288.6M |
8季度趋势，按日历期对齐
经营现金流IOVARBCAA
| Q4 25 | $-52.6M | $168.2M | ||
| Q3 25 | $-78.7M | $33.3M | ||
| Q2 25 | $-67.4M | $8.4M | ||
| Q1 25 | $-103.7M | $93.2M | ||
| Q4 24 | $-73.3M | $149.0M | ||
| Q3 24 | $-59.0M | $51.3M | ||
| Q2 24 | $-98.4M | $4.0M | ||
| Q1 24 | $-122.3M | $71.2M |
自由现金流IOVARBCAA
| Q4 25 | $-61.9M | $161.1M | ||
| Q3 25 | $-89.5M | $30.8M | ||
| Q2 25 | $-74.9M | $5.2M | ||
| Q1 25 | $-109.9M | $91.6M | ||
| Q4 24 | $-77.5M | $143.2M | ||
| Q3 24 | $-61.3M | $49.8M | ||
| Q2 24 | $-98.9M | $2.7M | ||
| Q1 24 | $-126.5M | $69.1M |
自由现金流率IOVARBCAA
| Q4 25 | -71.3% | 170.9% | ||
| Q3 25 | -132.7% | 32.9% | ||
| Q2 25 | -124.9% | 5.5% | ||
| Q1 25 | -222.8% | 67.4% | ||
| Q4 24 | -105.1% | 160.0% | ||
| Q3 24 | -104.6% | 56.5% | ||
| Q2 24 | -317.9% | 3.1% | ||
| Q1 24 | -17685.3% | 57.5% |
资本支出强度IOVARBCAA
| Q4 25 | 10.7% | 7.5% | ||
| Q3 25 | 16.1% | 2.6% | ||
| Q2 25 | 12.4% | 3.5% | ||
| Q1 25 | 12.6% | 1.2% | ||
| Q4 24 | 5.7% | 6.5% | ||
| Q3 24 | 3.9% | 1.7% | ||
| Q2 24 | 1.4% | 1.5% | ||
| Q1 24 | 583.4% | 1.7% |
现金转化率IOVARBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RBCAA
暂无分部数据
